DR. MICHAEL ZELIGS
Anesthesiologist Assistant at Balsam Ave, Boulder, CO

6416793, Jul 9, 2002

Jul 11, 2000

09/614007

Michael A. Zeligs - Boulder CO
Irwin C. Jacobs - Eureka MO

BioResponse, L.L.C. - Boulder CO

A61K 3578

424725, 424775, 424489, 424490, 424492

The present invention relates to spray dried hydrophobic phytochemical (i. e. , yohimbine and ibogaine) compositions, a process for making such compositions and a method of using such compositions for, e. g. , the promotion of weight loss. Typically, the hydrophobic dietary compositions of the present invention exhibit enhanced absorptivity when taken orally.

6534085, Mar 18, 2003

Sep 23, 1999

09/404112

Michael A. Zeligs - Boulder CO

BioResponse L.L.C. - Boulder CO

A61K 948

424451, 424464, 424450, 424458, 424488, 424489, 424486, 424401, 424439, 424 45, 424725, 424736, 514323

New dietary supplement compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3′ diindolylmethane (LTR-1), dietary supplement acceptable carriers and/or excipients. The use of these dietary supplement compositions facilitate weight loss as part of a nutritional system targeting release and metabolism of stored fat.

2004022, Nov 11, 2004

Feb 6, 2004

10/774324

Michael Zeligs - Boulder CO, US

BioResponse, LLC

A61K031/405, A61K031/195

514/419000, 514/564000

Synergistic compositions and methods are disclosed for using cruciferous indoles with iron/zinc chelators in the treatment of papillomavirus-related conditions. These synergistic compositions of diindolylymethane (DIM), related trimeric derivatives, and related indole derivatives include combinations with deferoxamine, deferiprone, bipyridyl, Desferri-exochelin, picolinic acid, 3-hydroxypicolinic acid, and sodium butyrate as iron/zinc chelators. The methods described comprise more effective therapies for common cutaneous warts (verrucae) and related dysplasias of the oropharynx, genitalia, and uterine cervix.

2005006, Mar 24, 2005

Jun 24, 2004

10/877097

Michael Zeligs - Boulder CO, US

A61K051/00, A61K031/555, A61K031/405, A61K035/78

424001110, 424755000, 514184000, 514566000, 514419000

This abstract describes eliminating the need for cutting up manufactured synthetic filament polymer yarns (for examples, nylon and Kevlar) into wool and linen lengths and respinning these again into yarns approaching wool and linen like wear properties in clothing and other textiles at significant reductions in production costs accomplished by using laser pierced holes in the plates of and adding continuous wave or pulsed sonic generators to the rear of spinneret housings through which viscous polymer fluids flow both of which produce surface irregularities in the yarns (longitudinal and circumferential ridges in valleys) in the spun continuous filaments approaching wear properties of natural wool and linen.

2006011, May 25, 2006

Oct 26, 2005

11/260543

Michael Zeligs - Boulder CO, US

A61K 31/655, A61K 31/405, A61K 31/407

514410000, 514414000, 514151000

The present invention includes compositions and methods for the treatment and prevention of conditions associated with Human Cytomegalovirus (HCMV) infection. HCMV-associated conditions include infections (active and latent), benign cell-proliferative conditions, pre-cancerous cell-proliferative conditions, and cancerous conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, in combination with an inhibitor of a membrane bound Growth Factor Receptor (GFR), to treat conditions associated with exposure to HCMV. In certain embodiments, the compositions of the invention can be used in combination with radiation therapy.

7989486, Aug 2, 2011

Dec 30, 2005

11/322803

Michael A. Zeligs - Boulder CO, US

Bioresponse, L.L.C. - Boulder CO

A61K 31/405, A61K 38/00, A61K 31/69, A61K 31/59, A61K 31/33, A61K 31/05

514415, 514 11, 514 64, 514733, 514183, 514167

The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with an inhibitor of a membrane bound Epidermal Growth Factor Receptor (EGFR) inhibitors, to treat conditions associated with exposure to RSV.

2006026, Nov 23, 2006

Mar 28, 2006

11/392840

Michael Zeligs - Boulder CO, US

A61K 31/404

514414000

The present invention includes compositions and methods for the treatment and prevention of oral mucosal disorders and for promotion of bone health. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with anti-inflammatory agents and/or antibacterial agents, to treat oral mucosal disorders and promote bone health. The compositions of the invention are used to prevent and reverse oral mucosal disorders and bone loss (osteopenia and osteoporosis) associated with aging and chronic inflammation. Oral mucosal disorders include Periodontitis, gingivitis and related oral mucosal inflammation. Formulations of the compositions of the invention include capsules, tablets, toothpastes, oral gels, mouthwashes, mouth rinses, lozenges, chewing gum, dental floss, and dental topical formulations, and fortified foods.

8586621, Nov 19, 2013

Oct 26, 2007

12/447307

Michael A. Zeligs - Boulder CO, US

A61K 31/40, A61K 31/405, A61K 9/48, A61K 9/20, A61K 9/00

514415, 514414, 514420, 424451, 424464, 424400

The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.

7384972, Jun 10, 2008

Jan 26, 2004

10/765792

Michael A. Zeligs - Boulder CO, US

BioResponse L.L.C. - Boulder CO

A61K 31/403, A61K 31/404, A61K 9/127

514419, 424489, 424 131

New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3′diindolylmethane (LTR-1), acceptable carriers and/or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia and endometriosis.

2014003, Feb 6, 2014

Oct 10, 2013

14/051248

Michael A. Zeligs - Boulder CO, US

C07D 209/04, C07D 209/52, A61K 31/407, A61K 31/357, A61K 31/4706, A61K 31/12, A61K 31/49, A61K 31/155, A61K 31/4164, A61K 33/24, A61K 36/258, A61K 36/06, A61K 36/886, A61K 38/19, A61K 31/59, A61K 36/8962, A61K 36/00, A61K 31/404

424 851, 514415, 514410, 514313, 514305, 514311, 514396, 5142278, 424651, 424728, 42419515, 424744, 514167, 424754, 424725

The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.